Helping you make wiser investment decisions

Pharmaceuticals, health and wellness

Roche gets a green light to challenge Biogen, Novartis with SMA med Evrysdi

A third spinal muscular atrophy treatment is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam. The medicine offers at-home dosing for patients, potentially giving it an edge versus the competition during the COVID-19 pandemic.  Another potential edge? Price. Genentech set Evrysdi’s list price at up to $340,000 per year, depending on a patient’s weight. For some younger patients, […]

Alexion hires first chief diversity officer, following pharma peers and social sentiment

Alexion Pharmaceuticals named its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion. Alexion joins a majority of Big Pharma with C-level execs focused on diversity, particularly relevant in the current social climate—and as white men still dominate top positions across the industry. Uzair Qadeer will fill the role, moving from […]

Pfizer’s Lorbrena makes play for earlier lung cancer use with Xalkori-topping data

If Pfizer wants targeted lung cancer med Lorbrena to be a true follow-up to Xalkori, it has to get the product cleared in previously untreated ALK-positive patients. And it just took a step toward achieving that goal. In a phase 3 trial, Lorbrena showed it could outdo predecessor Xalkori at keeping lung cancer progression at […]

Novartis eyes 3rd Kymriah indication with follicular lymphoma trial win

Novartis is hoping a third indication will help position Kymriah better against Gilead Sciences’ rival Yescarta in the CAR-T race—and it has positive early clinical results to back its case. Kymriah has hit its goal of eradicating signs of cancer in patients with relapsed or refractory follicular lymphoma (r/r FL) at an interim analysis of the phase 2 Elara […]

In a first, MorphoSys, Incyte win Monjuvi FDA nod in lymphoma to challenge Roche’s Polivy

The FDA hasn’t specifically approved a therapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after an initial line of therapy—until now. MorphoSys and Incyte’s Monjuvi—also known as tafasitamab—in combination with Celgene’s Revlimid now represents the first FDA-approved second-line regimen for DLBCL, the two companies said Friday. Because of Monjuvi’s importance […]

Merck’s cancer meds keep churning amid COVID-19, but vaccines stumble

Earlier this year, Merck warned investors that the COVID-19 pandemic would take a multbillion-dollar bite out of its revenue expectations for 2020. And in the second quarter, that prediction took shape. The pandemic hurt Merck’s pharmaceutical sales by about $1.5 billion from April to June, the drugmaker reported, despite continued growth for its cancer medicines. Sales for […]

Pfizer, BioNTech keep COVID vaccine deals rolling with 120M-dose Japan pact

With several COVID-19 vaccines now in late-stage testing, countries the world over are hustling to get their hands on their own supplies. Now, one of the leading duos in the inoculation race has inked its third supply pact in the span of two weeks. On Friday, American drugmaker Pfizer and its German mRNA partner BioNTech announced a deal with […]

Immunology launches buoy AbbVie sales as COVID-19 swamps ex-Allergan aesthetics biz

Only months into its massive merger with Allergan, AbbVie has been forced to contend with a pandemic challenge to its brand-new aesthetics business. But thanks to new meds that are outperforming expectations, AbbVie is holding steady. Driven by growing sales for two superstar launches, psoriasis med Skyrizi and rheumatoid arthritis drug Rinvoq, AbbVie offset a COVID-19 downturn for its nascent […]

As Trump pledges lower drug prices—again—pharma CEOs voice skepticism with his plans

President Donald Trump on Thursday again pledged to quickly lower drug prices in the U.S. Stickers will “soon be lowered massively,” Trump tweeted Thursday, indirectly touting a group of executive orders he signed last Friday. But though Big Pharma CEOs called out their concerns with the plans during this week’s analyst calls—especially Trump’s effort to tie U.S. prices to lower […]

Pfizer lays out COVID-19 vaccine commercial strategy for pandemic and beyond

With its trials and pricing set, Pfizer has pulled back the curtain on the long-range commercial strategy for its COVID-19 vaccine. During its earnings call Tuesday, execs laid out two phases, pandemic and seasonal, with some combination of the two likely to play out over the next several years. The current pandemic phase, expected to continue […]

Which pharma advertising did President Trump lambaste on Twitter? Good question

President Donald Trump slammed “Big Pharma” TV ads on Twitter, the morning after pharma executives turned down his White House invite. But the ad that sparked his ire might not be a pharma commercial after all. While the president may have been upset by the pharma executives’ rejection, a TV ad created by the Pharmaceutical Care […]

Europe’s COVID-19 vaccine negotiations hit snags with 3 drugmakers: Reuters

Numerous drugmakers are racing ahead with COVID-19 vaccine programs, and some have begun taking orders from governments to deliver hundreds of millions of doses if their candidates succeed. But negotiations between the EU and some companies have hit snags, Reuters reports. The EU is negotiating with at least six COVID-19 vaccine developers, but sources told […]